Aggregate collaboration transaction amount.

No definition available.

Name:	ctmx_AggregateCollaborationTransactionAmount
Namespace Prefix:	ctmx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Change in estimated collaboration transaction amount.

+ References

No definition available.

+ Details

Name:	ctmx_ChangeInEstimatedCollaborationTransactionAmount
Namespace Prefix:	ctmx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Contingent payments receivable profit split on sales.

+ References

No definition available.

+ Details

Name:	ctmx_ContingentPaymentsReceivableProfitSplitOnSales
Namespace Prefix:	ctmx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Contingent payments receivable upon achieving development, regulatory and commercial milestones.

+ References

No definition available.

+ Details

Name:	ctmx_ContingentPaymentsReceivableUponAchievingDevelopmentRegulatoryAndCommercialMilestones
Namespace Prefix:	ctmx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Estimated research service period.

+ References

No definition available.

+ Details

Name:	ctmx_EstimatedResearchServicePeriod
Namespace Prefix:	ctmx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Estimated sublicense fees.

+ References

No definition available.

+ Details

Name:	ctmx_EstimatedSublicenseFees
Namespace Prefix:	ctmx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestone payment received.

+ References

No definition available.

+ Details

Name:	ctmx_MilestonePaymentReceived
Namespace Prefix:	ctmx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone payments receivable.

+ References

No definition available.

+ Details

Name:	ctmx_MilestonePaymentsReceivable
Namespace Prefix:	ctmx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Milestone payments received from revenue recognized during period.

+ References

No definition available.

+ Details

Name:	ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod
Namespace Prefix:	ctmx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of accounting units.

+ References

No definition available.

+ Details

Name:	ctmx_NumberOfAccountingUnits
Namespace Prefix:	ctmx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of collaboration agreements.

+ References

No definition available.

+ Details

Name:	ctmx_NumberOfCollaborationAgreements
Namespace Prefix:	ctmx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of targets.

+ References

No definition available.

+ Details

Name:	ctmx_NumberOfTargets
Namespace Prefix:	ctmx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of targets selected.

+ References

No definition available.

+ Details

Name:	ctmx_NumberOfTargetsSelected
Namespace Prefix:	ctmx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Payments of sublicense fees.

+ References

No definition available.

+ Details

Name:	ctmx_PaymentsOfSublicenseFees
Namespace Prefix:	ctmx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage of net Income or net losses related to development and commercialization costs.

+ References

No definition available.

+ Details

Name:	ctmx_PercentageOfNetIncomeOrNetLossesRelatedToDevelopmentAndCommercializationCosts
Namespace Prefix:	ctmx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Cash received from collaborators during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromCollaborators
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.

+ References

No definition available.

+ Details

Name:	us-gaap_TypeOfRevenueExtensibleList
Namespace Prefix:	us-gaap_
Data Type:	enum2:enumerationSetItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=ctmx_SecondTargetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ctmx_CD71AgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ctmx_SeattleGeneticsAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ctmx_DiscoveryAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration and License Agreements - AbbVie Ireland Unlimited Company - Additional Information (Details) $ in Thousands	1 Months Ended						3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2022 USD ($)	Mar. 31, 2020 USD ($)	Jun. 30, 2019 USD ($)	May 31, 2018 USD ($)	Jul. 31, 2017 USD ($)	Apr. 30, 2016 USD ($) AccountingUnit Agreement Target	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Jun. 30, 2022 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Mar. 31, 2017 Target
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized							$ 11,147	$ 12,853	$ 9,040	$ 21,893	$ 33,040	$ 53,163	$ 37,312
Type of Revenue [Extensible List]												us-gaap:LicenseAndServiceMember	us-gaap:LicenseAndServiceMember
Deferred revenue	$ 301,326											$ 301,326	$ 284,760	$ 318,707
AbbVie Ireland Unlimited Company
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized		$ 26,600		$ 9,900			$ 2,972	$ 6,775	$ 1,751	$ 8,526	$ 11,498
AbbVie Ireland Unlimited Company \| ASC 606
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received						$ 30,000
Milestone payment received						14,000
Total transaction price						39,800
Estimated sublicense fees						$ 4,200
Number of accounting units \| AccountingUnit						2
AbbVie Ireland Unlimited Company \| Second Target
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Change in estimated collaboration amount	4,400
AbbVie Ireland Unlimited Company \| Collaborative Arrangement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of collaboration agreements \| Agreement						2
Percentage of net profits or net losses related to development and commercialization costs						35.00%
AbbVie Ireland Unlimited Company \| CD71 Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received						$ 20,000						100,000
Milestone payments received		40,000		21,000	$ 14,000							100,000
Total transaction price						29,800
Milestone payment received		$ 40,000		21,000
Deferred revenue	4,000											4,000	16,100
AbbVie Ireland Unlimited Company \| CD71 Agreement \| Transferred over Time
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Type of Revenue [Extensible List]		us-gaap:LicenseAndServiceMember
AbbVie Ireland Unlimited Company \| CD71 Agreement \| ASC 606
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received						20,000
Estimated sublicense fees						4,200
Milestone payment received						$ 14,000
AbbVie Ireland Unlimited Company \| CD71 Agreement \| U.S
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Profit split on U.S. sales						35.00%
AbbVie Ireland Unlimited Company \| CD71 Agreement \| Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contingent payments receivable upon achieving development, regulatory and commercial milestones						$ 470,000
AbbVie Ireland Unlimited Company \| Seattle Genetics Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Sublicense fees paid				$ 4,000	$ 1,000
AbbVie Ireland Unlimited Company \| Seattle Genetics Agreement \| ASC 606
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Sublicense fees paid						1,000
AbbVie Ireland Unlimited Company \| Discovery Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received						10,000
Number of targets selected \| Target															1
Total transaction price						10,000
Deferred revenue	$ 0											$ 0	$ 6,500
AbbVie Ireland Unlimited Company \| Discovery Agreement \| ASC 606
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received						10,000
AbbVie Ireland Unlimited Company \| Discovery Agreement \| Second Target
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments received			$ 10,000			$ 10,000
AbbVie Ireland Unlimited Company \| Discovery Agreement \| Second Target \| ASC 606
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total transaction price			$ 10,000
Estimated research service period			5 years
AbbVie Ireland Unlimited Company \| Discovery Agreement \| Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of targets \| Target						2